This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, H. H. Articles by Berenson, J. R. Search for Related Content PubMed PubMed Citation Articles by Yang, H. H. Articles by Berenson, J. R.

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

From the Institute for Myeloma and Bone Cancer Research; and the David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.

Address reprint requests to Hank H. Yang, MD, PhD, Institute for Myeloma and Bone Cancer Research, 1875 Century Park East, Suite 300, Los Angeles, CA 90067; e-mail: hyang{at}myelomasource.org.

Drug resistance remains a major clinical challenge for cancer treatment. Early studies suggested that overexpression of P-glycoprotein was a major contributor to the chemotherapy resistance of myeloma cells and other tumor cells. Attempts in several clinical studies to reverse multidrug resistance protein (MDR) by using MDR modulators have not yet generated promising results. Recently, the emerging knowledge about the importance of overcoming antiapoptosis and drug resistance in treating a variety of malignancies, including multiple myeloma (MM), raises new hope of improving the treatment outcome for patients with cancer. The therapeutic value of targeting therapies that aim to reverse the antiapoptotic process in MM cells has been explored in a number of experimental systems, and the results have been promising. The proteasome inhibitor PS-341 is a new specifically targeted proapoptotic therapy that has been tested in clinical studies. The results indicate that PS-341 alone is an effective therapy for patients with MM who experience disease relapse. Recent in vitro data also demonstrate that PS-341 can markedly sensitize chemotherapy-resistant MM cells to various chemotherapeutic agents. On the basis of these encouraging results, clinical studies are underway to test the efficacy of PS-341 and chemotherapeutic agents as combination therapy in treating patients with refractory and relapsed MM.

This article has been cited by other articles:

				T. Khong, J. Sharkey, and A. Spencer The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma Haematologica, June 1, 2008; 93(6): 860 - 869. [Abstract] [Full Text] [PDF]

				S. Cohen, R. Cahan, E. Ben-Dov, M. Nisnevitch, A. Zaritsky, and M. A. Firer Specific Targeting to Murine Myeloma Cells of Cyt1Aa Toxin from Bacillus thuringiensis Subspecies israelensis J. Biol. Chem., September 28, 2007; 282(39): 28301 - 28308. [Abstract] [Full Text] [PDF]

				F. A. Piazza, M. Ruzzene, C. Gurrieri, B. Montini, L. Bonanni, G. Chioetto, G. Di Maira, F. Barbon, A. Cabrelle, R. Zambello, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2 Blood, September 1, 2006; 108(5): 1698 - 1707. [Abstract] [Full Text] [PDF]

				R. Z. Orlowski, P. M. Voorhees, R. A. Garcia, M. D. Hall, F. J. Kudrik, T. Allred, A. R. Johri, P. E. Jones, A. Ivanova, H. W. Van Deventer, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood, April 15, 2005; 105(8): 3058 - 3065. [Abstract] [Full Text] [PDF]

				T. Al-Saleem and H. Al-Mondhiry Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms Blood, March 15, 2005; 105(6): 2274 - 2280. [Abstract] [Full Text] [PDF]